Gotham Asset Management’s Immunovant IMVT Stock Holding History

Gotham Asset Management’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-5,527	Closed	-$212K	–	1379
2023 Q3	$212K	Buy	+5,527	New	+$125K	﹤0.01%	1221

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Gotham Asset Management's IMVT Position: Q4 2023 in Review

Gotham Asset Management sold out of Immunovant (IMVT) in Q4 2023, closing a stake of 5,527 shares — an estimated $212K sold.

Gotham Asset Management first reported a position in IMVT in Q3 2023 and held it in 1 quarter. The position peaked at $212K in Q3 2023. 228 funds tracked by Wall St. Rank hold IMVT as of Q4 2023.

Gotham Asset Management reported no remaining Immunovant position as of Q4 2023 after selling out during the quarter.
Gotham Asset Management sold 5,527 Immunovant shares in Q4 2023, an estimated $212K.
Gotham Asset Management first reported a position in Immunovant in Q3 2023 and held it in 1 quarter.
Gotham Asset Management's Immunovant position peaked at $212K in Q3 2023.
228 funds tracked by Wall St. Rank held Immunovant as of Q4 2023.

Based on Gotham Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.